SMMT Summit Therapeutics Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
23:56
Aug 03
Aug 03
CNBC
Summit Therapeutics speculative biotech with insider buying.
Summit Therapeutics has heavy insider buying ($50M by co-CEO, $5M by management), is awaiting FDA approval with trial results better than an existing drug, and can be treated as a speculative buy for risk-tolerant investors.
SMMT
Summit Therapeutics
Long
1ST
—
—
05:36
Jan 16
Jan 16
Bloomberg Markets
Akeso drug approval odds look good.
Akeso's PD-1/VEGF bispecific ivonescimab, partnered with Summit Therapeutics, has good FDA approval odds based on four successful Phase III studies and consistent safety/efficacy data. The company sees multiple 2026 catalysts, including potential US approval and additional indications, plus pipeline optionality in bispecific ADCs, immunology, and Alzheimer's.
SMMT
Summit Therapeutics
Long
1ST
—
—
About SMMT Investor Commentary
Across the available history and selected sources, Buzzberg tracks SMMT (Summit Therapeutics) across 10 sources: 2 bullish vs 0 bearish calls from 11 authors. Historical directional balance: 13% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 15 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Jim Cramer, Bing Wang.